1. Home
  2. PCRX vs KW Comparison

PCRX vs KW Comparison

Compare PCRX & KW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • KW
  • Stock Information
  • Founded
  • PCRX 2006
  • KW 1977
  • Country
  • PCRX United States
  • KW United States
  • Employees
  • PCRX N/A
  • KW N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • KW Real Estate
  • Sector
  • PCRX Health Care
  • KW Finance
  • Exchange
  • PCRX Nasdaq
  • KW Nasdaq
  • Market Cap
  • PCRX 1.2B
  • KW 940.4M
  • IPO Year
  • PCRX 2011
  • KW 1992
  • Fundamental
  • Price
  • PCRX $22.90
  • KW $7.58
  • Analyst Decision
  • PCRX Buy
  • KW Hold
  • Analyst Count
  • PCRX 8
  • KW 1
  • Target Price
  • PCRX $28.38
  • KW $13.00
  • AVG Volume (30 Days)
  • PCRX 545.0K
  • KW 1.3M
  • Earning Date
  • PCRX 07-29-2025
  • KW 08-06-2025
  • Dividend Yield
  • PCRX N/A
  • KW 6.18%
  • EPS Growth
  • PCRX N/A
  • KW N/A
  • EPS
  • PCRX N/A
  • KW N/A
  • Revenue
  • PCRX $702,772,000.00
  • KW $514,600,000.00
  • Revenue This Year
  • PCRX $7.54
  • KW $31.15
  • Revenue Next Year
  • PCRX $10.78
  • KW $2.98
  • P/E Ratio
  • PCRX N/A
  • KW N/A
  • Revenue Growth
  • PCRX 3.08
  • KW N/A
  • 52 Week Low
  • PCRX $11.16
  • KW $5.98
  • 52 Week High
  • PCRX $27.64
  • KW $11.88
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.82
  • KW 66.92
  • Support Level
  • PCRX $22.82
  • KW $7.16
  • Resistance Level
  • PCRX $23.83
  • KW $7.83
  • Average True Range (ATR)
  • PCRX 0.74
  • KW 0.24
  • MACD
  • PCRX -0.02
  • KW 0.08
  • Stochastic Oscillator
  • PCRX 6.22
  • KW 79.10

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About KW Kennedy-Wilson Holdings Inc.

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

Share on Social Networks: